Trials / Completed
CompletedNCT03884023
Effect of REST in the Alzheimer Disease Continuum
Effect of REST on Cognitive Function and Hippocampus in the Alzheimer Disease Continuum
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 300 (actual)
- Sponsor
- Dongzhimen Hospital, Beijing · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Accepted
Summary
The investigators assume that REST gene polymorphism affects REST protein concentration, and REST protein concentration in peripheral blood is related to cognitive function and hippocampus. In this current study, REST protein content and gene polymorphism will be obtained in peripheral blood in AD and normal control. The effect of REST gene polymorphism on REST protein concentration will be discovered.The relationship between REST protein concentration and cognitive function will be found, as well as the relationship between REST protein concentration and hippocampus.
Detailed description
Repressor element silencing transcription factor(REST), also known as neuron-restrictive silencer factor (NRSF) is a zinc finger protein of 121 kD and belongs to the Gli-Kruppel family with transcriptional regulation.This will be a Case-Crossover research. Consecutive participants will be divided into Alzheimer's disease dementia group, mild cognitive impairment due to Alzheimer's disease group and normal control group according to inclusion criteria of this research. Peripheral blood samples will be retained to detect REST gene polymorphisms and protein concentrations. Participants perform neuropsychological tests to assess cognitive function. Medial temporal atrophy scale is used to describe hippocampus. Differences in the mean or proportions between these 3 groups will be checked by t test or test. The relationship between REST protein concentration and cognitive function will be estimated, as well as the relationship between REST protein concentration and hippocampus.
Conditions
Timeline
- Start date
- 2019-06-28
- Primary completion
- 2020-11-30
- Completion
- 2020-11-30
- First posted
- 2019-03-21
- Last updated
- 2022-03-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03884023. Inclusion in this directory is not an endorsement.